AMGN logo

AMGNAMGEN Inc.

$355.20
$1.14
(0.32%)
Today
Closed $355.20
$0.91
(0.26%)
After Hours
Updated: 07:57 PM EDT
EarningsAug 4
Mkt Cap$191.7B
Vol2.73M
News
all
press releases
Is Amgen Inc. (AMGN) A Good Stock To Buy Now?
Is Amgen Inc. (AMGN) A Good Stock To Buy Now...
Yahoo! Finance: News
News Placeholder
More News
News Placeholder
Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Amgen (AMGN) stood at $337.5, denoting a -2.05% move from the preceding trading day.
Zacks
News Placeholder
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Zacks
News Placeholder
Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?
MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.
Zacks
News Placeholder
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
SNY wins EU approval for a subcutaneous Sarclisa option in multiple myeloma, offering faster administration and flexible delivery methods.
Zacks
News Placeholder
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks
News Placeholder
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS PR Newswire THOUSAND OAKS, Calif., June 7, 2026 VESALIUS-CV...
PR Newswire
News Placeholder
Amgen: A Biotech Giant's Path to Recovery and Growth
Explore the exciting world of Amgen (NASDAQ: AMGN) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!*Stock prices used were the prices of Apr...
Nasdaq News: Markets
News Placeholder
Can JNJ Sustain Growth Amid Patent, Legal and China Risks?
J&J faces Stelara erosion, China MedTech pressure and talc litigation, but targets $100B revenues and faster growth in 2026.
Zacks
News Placeholder
AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., June 4, 2026 THOUSAND OAKS, Calif., June 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the...
PR Newswire
<
1
2
...
>

Advertisement|Remove ads.